Robert Renninger - Athira Pharma Director Reporting
| ATHA Stock | USD 0.33 0.02 5.71% |
Insider
Robert Renninger is Director Reporting of Athira Pharma
| Age | 41 |
| Address | 18706 North Creek Parkway, Bothell, WA, United States, 98011 |
| Phone | 425 620 8501 |
| Web | https://www.athira.com |
Latest Insider Transactions
Robert Renninger Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Renninger against Athira Pharma stock is an integral part of due diligence when investing in Athira Pharma. Robert Renninger insider activity provides valuable insight into whether Athira Pharma is net buyers or sellers over its current business cycle. Note, Athira Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Athira Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Renninger over three months ago Insider Trading |
Athira Pharma Management Efficiency
The company has return on total asset (ROA) of (0.5523) % which means that it has lost $0.5523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1077) %, meaning that it created substantial loss on money invested by shareholders. Athira Pharma's management efficiency ratios could be used to measure how well Athira Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.57. In addition to that, Return On Capital Employed is expected to decline to -2.32. The current year's Other Current Assets is expected to grow to about 4.2 M, whereas Total Assets are forecasted to decline to about 55.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD FACP | NextCure | 71 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| David Hanley | Nuvation Bio | 55 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| David MD | Nuvation Bio | 55 | |
| Stacy Markel | Nuvation Bio | 60 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| James Brady | Spero Therapeutics | N/A | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Satyavrat CFA | Spero Therapeutics | 52 | |
| Hoyoung MD | CytomX Therapeutics | 56 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| MBA BS | CytomX Therapeutics | 46 | |
| Dr IV | Assembly Biosciences | 53 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Iraj Ali | Achilles Therapeutics PLC | 50 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Solomon Langermann | NextCure | 66 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Sumita JD | Instil Bio | 50 | |
Management Performance
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.55 |
Athira Pharma Leadership Team
Elected by the shareholders, the Athira Pharma's board of directors comprises two types of representatives: Athira Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Athira. The board's role is to monitor Athira Pharma's management team and ensure that shareholders' interests are well served. Athira Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Athira Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark JD, General Secretary | ||
| Samantha Willing, Executive People | ||
| Robert Renninger, Director Reporting | ||
| Dr MBA, CEO President | ||
| Kevin Church, Chief Officer | ||
| Javier MD, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| Glenna Mileson, Chief Officer | ||
| Rachel MBA, Chief Officer | ||
| Julie Rathbun, Head Relations | ||
| Andrew Gengos, CFO Officer |
Athira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Athira Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | (37.44 M) | ||||
| Shares Outstanding | 39.04 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 51.80 % | ||||
| Number Of Shares Shorted | 888.01 K | ||||
| Price To Book | 0.28 X | ||||
| EBITDA | (100.9 M) | ||||
| Net Income | (96.94 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.